# Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-conferenc-a2e97fe3
Ticker: AKBA
Company: Akebia Therapeutics
Source: Akebia Therapeutics
Published: 2026-05-28 12:00 EST
## Summary

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the...

## Article Body
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com . A replay of the webcast will also be available for 90 days following the presentation.

The 2026 Jefferies Global Healthcare Conference will take place June 2-4, 2026, in New York, NY.

About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com , which does not form a part of this release.

Akebia Therapeutics Contact Mercedes Carrasco mcarrasco@akebia.com
## Recent Company News
- 2026-07-02 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-bc8c2359) — Source: Akebia Therapeutics
- 2026-06-30 12:00 EST — [U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA](https://biopharmsignal.com/news/AKBA/u-s-renal-care-and-akebia-announce-interim-analysis-of-voice-trial-demonstrated--7cc9c9bc) — Source: Akebia Therapeutics
- 2026-06-10 12:00 EST — [Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-strengthens-vafseo-vadadustat-patent-portfolio-17cb62c9) — Source: Akebia Therapeutics
- 2026-06-01 20:05 EST — [Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-eb3ccebf) — Source: Akebia Therapeutics
- 2026-05-28 12:00 EST — [Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/AKBA/akebia-therapeutics-to-present-at-the-2026-jefferies-global-healthcare-conferenc-a2e97fe3) — Source: Akebia Therapeutics
## Related News
- 2026-07-29 10:30 EST — BSX — [Boston Scientific announces results for second quarter 2026](https://biopharmsignal.com/news/BSX/boston-scientific-announces-results-for-second-quarter-2026-cbac35ee)
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)